AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27105563 — intervention group
Group type: COMPARATOR
Intervention: Challenge dose of monovalent vaccine
Number of subjects: 209
Study 25230081 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.4 mm base curvature (BC) Acuvue Oasys bandage soft contact lens
Number of subjects: 140
Study 25230081 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.8 mm base curvature (BC) Acuvue Oasys bandage soft contact lens
Number of subjects: 140
Study 25230081 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens loss
Number of subjects: 140
Study 23407285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine application
Number of subjects: 140
Study 23407285 — intervention group
Group type: COMPARATOR
Intervention: Conventional dry care
Number of subjects: 140
Study 20299247 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis (DO)
Number of subjects: 0
Study 20299247 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthognathic surgery (CO)
Number of subjects: 0
Study 18547300 — intervention group
Group type: EXPERIMENTAL
Intervention: infliximab
Number of subjects: 7931
Study 18547300 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept
Number of subjects: 7931
Study 18547300 — intervention group
Group type: EXPERIMENTAL
Intervention: efalizumab
Number of subjects: 7931
Study 18547300 — intervention group
Group type: EXPERIMENTAL
Intervention: alefacept
Number of subjects: 7931
Study 18547300 — intervention group
Group type: EXPERIMENTAL
Intervention: efalizumab (sensitivity analysis)
Number of subjects: 7931
Study 18547300 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7931
Study 17189547 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Load (HG) diet
Number of subjects: 34
Study 17189547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (LG) diet
Number of subjects: 34
Study 17189547 — intervention group
Group type: COMPARATOR
Intervention: Both diets (HG and LG)
Number of subjects: 34
Study 14581730 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 46
Study 14581730 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 46
Study 14581730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 10763172 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline-Dexpanthenol nasal spray
Number of subjects: 61
Study 10763172 — intervention group
Group type: COMPARATOR
Intervention: Xylometazoline nasal spray
Number of subjects: 61
Study 9158632 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 620
Study 8427429 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg nalmefene IV
Number of subjects: 53
Study 8427429 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nalmefene IV
Number of subjects: 53
Study 8427429 — intervention group
Group type: EXPERIMENTAL
Intervention: nalmefene
Number of subjects: 53
Study 3478618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone for at least a two-year period
Number of subjects: 183
Study 3478618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 31744848 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-level interventions for non-communicable diseases
Number of subjects: 0
Study 31744848 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural experiments
Number of subjects: 0
Study 31744848 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based evidence pathway
Number of subjects: 0
Study 29172732 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan monotherapy
Number of subjects: 175
Study 29172732 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichlormethiazide
Number of subjects: 175
Study 29172732 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine
Number of subjects: 175
Study 29172732 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 175
Study 29172732 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Irbesartan + Trichlormethiazide/Amlodipine/Efonidipine)
Number of subjects: 175
Study 26648488 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game intervention (AVGs)
Number of subjects: 21
Study 26648488 — intervention group
Group type: COMPARATOR
Intervention: No active video games (control)
Number of subjects: 21
Study 24596456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (80 mg/2 mL)
Number of subjects: 9
Study 24596456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL isotonic saline)
Number of subjects: 9
Study 22954563 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration sodium bicarbonate (833 mEq/L, n = 87)
Number of subjects: 123
Study 22954563 — intervention group
Group type: COMPARATOR
Intervention: Low-concentration sodium bicarbonate (160 mEq/L, n = 36)
Number of subjects: 123
Study 20678992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 60
Study 20678992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18477078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative natural sound (soft wind and twitter)
Number of subjects: 32
Study 18477078 — intervention group
Group type: COMPARATOR
Intervention: No sounds (control group)
Number of subjects: 32
Study 16178000 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve stimulation (PNS)
Number of subjects: 30
Study 16178000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 30
Study 12842170 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutically induced weight gain during 11 weeks of re-feeding
Number of subjects: 18
Study 12842170 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutically induced weight gain after reaching target weight (11-20 weeks, mean 14.3±3)
Number of subjects: 18
Study 12842170 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of lg10 leptin levels with BMI increments during re-feeding
Number of subjects: 18
Study 12842170 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI increments between weeks 7 and 11
Number of subjects: 18
Study 9886454 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg 1alpha(OH)D3 daily (treatment group, n=43)
Number of subjects: 86
Study 9886454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n=43)
Number of subjects: 86
Study 9886454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86
Study 9886454 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg 1alpha(OH)D3 daily (treatment group)
Number of subjects: 86
Study 8889259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (dry powder 20 mg per inhalation and aqueous nasal spray 5.2 mg per dose)
Number of subjects: 118
Study 8889259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching dry powder and nasal spray)
Number of subjects: 118
Study 1735336 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg loperamide
Number of subjects: 12
Study 1735336 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg loperamide oxide
Number of subjects: 12
Study 1735336 — intervention group
Group type: COMPARATOR
Intervention: 2 mg loperamide oxide
Number of subjects: 12
Study 1735336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6084120 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz
Number of subjects: 26
Study 6084120 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 26
Study 31729355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia with neuromuscular blockade
Number of subjects: 81
Study 31729355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia with neuromuscular blockade during noxious stimulation
Number of subjects: 81
Study 29561907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training (12-week programme)
Number of subjects: 32
Study 29561907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Pilates training)
Number of subjects: 32
Study 26758621 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 6
Study 26758621 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard NICU care)
Number of subjects: 6
Study 25370657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation iceball in phantom study
Number of subjects: 13
Study 25370657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation iceball in vivo
Number of subjects: 13
Study 25370657 — intervention group
Group type: COMPARATOR
Intervention: Comparison of phantom and in vivo findings
Number of subjects: 13
Study 22323626 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) applied to the superior parietal lobule (SPL) during a spatial short-term memory task.
Number of subjects: 0
Study 22323626 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS) applied to the superior parietal lobule (SPL) during a period of passive fixation.
Number of subjects: 0
Study 19159021 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline solution (100 mg/mL) applied with a microbrush plus scaling and root planing (SRP+T)
Number of subjects: 37
Study 19159021 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline solution (100 mg/mL) applied with a microbrush (T)
Number of subjects: 37
Study 19159021 — intervention group
Group type: COMPARATOR
Intervention: Saline with a microbrush plus scaling and root planing (SRP+S)
Number of subjects: 37
Study 19159021 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 37
Study 17844705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atkins diet
Number of subjects: 0
Study 17844705 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available diets (4 groups)
Number of subjects: 0
Study 17844705 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate diet
Number of subjects: 0
Study 16895678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephroprotective therapy (blockade of the renin-angiotensin system)
Number of subjects: 0
Study 16895678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle measures and pharmacological treatment of metabolic disorders
Number of subjects: 0
Study 12468166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg)
Number of subjects: 281
Study 12468166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 9447852 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index (BIS)
Number of subjects: 20
Study 9447852 — intervention group
Group type: COMPARATOR
Intervention: Targeted propofol concentration
Number of subjects: 20
Study 9447852 — intervention group
Group type: COMPARATOR
Intervention: Measured propofol concentration
Number of subjects: 20
Study 9447852 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS combined with treatment history
Number of subjects: 20
Study 9447852 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 20
Study 7620654 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate
Number of subjects: 10
Study 7620654 — intervention group
Group type: COMPARATOR
Intervention: Ispaghulahusk
Number of subjects: 10
Study 2228324 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline ethylenediamine (2.5 mg/kg)
Number of subjects: 9
Study 2228324 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline ethylenediamine (5.0 mg/kg)
Number of subjects: 9
Study 2228324 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline ethylenediamine (7.5 mg/kg)
Number of subjects: 9
Study 2228324 — intervention group
Group type: COMPARATOR
Intervention: Standard MCH provocation method
Number of subjects: 9
Study 55652 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 34
Study 55652 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 34
Study 55652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30475764 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARRT intervention (personalized, pragmatic, multi-domain Alzheimer's disease risk reduction intervention)
Number of subjects: 200
Study 30475764 — intervention group
Group type: EXPERIMENTAL
Intervention: SMARRT intervention
Number of subjects: 200
Study 30475764 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) control
Number of subjects: 200
Study 28044255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant (modified release) as augmentation therapy to SSRIs
Number of subjects: 50
Study 28044255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28044255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant
Number of subjects: 50
Study 26203098 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg oral iodine daily for 6 months
Number of subjects: 163
Study 26203098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 23147964 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 18
Study 23147964 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine 60 mg
Number of subjects: 18
Study 21718910 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 6753
Study 21718910 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 6753
Study 18972723 — intervention group
Group type: EXPERIMENTAL
Intervention: Elongated needle therapy
Number of subjects: 150
Study 18972723 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture therapy
Number of subjects: 150
Study 17057565 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy for neck pain
Number of subjects: 311
Study 14669965 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA supplementation (480 mg DHA, 80 mg EPA, 40 mg AA, 96 mg GLA, 24 mg alpha‐tocopheryl acetate)
Number of subjects: 50
Study 10738049 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 403
Study 10738049 — intervention group
Group type: COMPARATOR
Intervention: Sotalol or Propafenone (Control)
Number of subjects: 403
Study 8874562 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed intravenous fluids
Number of subjects: 18
Study 8874562 — intervention group
Group type: COMPARATOR
Intervention: Room temperature intravenous fluids (Control)
Number of subjects: 18
Study 1571882 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of risk of anal sex
Number of subjects: 612
Study 1571882 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in the efficacy of condoms
Number of subjects: 612
Study 1571882 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoyment of safer sex
Number of subjects: 612
Study 1571882 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 612
Study 6203546 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (LA, 160 mg once a day)
Number of subjects: 10
Study 6203546 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional propranolol (CP, 40 mg four times a day)
Number of subjects: 10
Study 6203546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 31897054 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative quantitative (CQUANT) format
Number of subjects: 108
Study 31897054 — intervention group
Group type: COMPARATOR
Intervention: Noncomparative qualitative (NQUAL) format
Number of subjects: 108
Study 31897054 — intervention group
Group type: COMPARATOR
Intervention: Noncomparative quantitative (NQUANT) format
Number of subjects: 108
Study 30229439 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg/kg/day) administered during the neovascularization phase of ROP (stage 2)
Number of subjects: 126
Study 30229439 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (control group)
Number of subjects: 126
Study 26853798 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-SLS dentifrice containing enzymes, colostrum, and low concentrations of zinc
Number of subjects: 90
Study 26853798 — intervention group
Group type: COMPARATOR
Intervention: SLS-containing dentifrice (Control Group 1)
Number of subjects: 90
Study 26853798 — intervention group
Group type: COMPARATOR
Intervention: SLS-containing dentifrice (Control Group 2)
Number of subjects: 90
Study 25336114 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab concentrations > 2.79 μg/mL
Number of subjects: 483
Study 25336114 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to infliximab (ATI) concentrations < 3.15 U/mL
Number of subjects: 483
Study 25336114 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab trough concentrations
Number of subjects: 483
Study 25336114 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to infliximab (ATI) concentrations
Number of subjects: 483
Study 24309401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily for 15 days
Number of subjects: 55
Study 24309401 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg once daily for 15 days
Number of subjects: 55
Study 24309401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no β‐blocker therapy)
Number of subjects: 55
Study 22050553 — intervention group
Group type: EXPERIMENTAL
Intervention: 'M' technique massage with carrier oil
Number of subjects: 60
Study 22050553 — intervention group
Group type: EXPERIMENTAL
Intervention: 'M' technique massage with mandarin oil
Number of subjects: 60
Study 22050553 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care
Number of subjects: 60
Study 20509074 — intervention group
Group type: EXPERIMENTAL
Intervention: Literal suggestions (L) such as 'your right arm is heavy'
Number of subjects: 0
Study 20509074 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphorical suggestions (M) such as 'your right arm is made of lead'
Number of subjects: 0
Study 20509074 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal sequence of suggestions (L followed by M)
Number of subjects: 0
Study 17158823 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic methods in randomised controlled trials
Number of subjects: 46
Study 17158823 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised procedure for radiographic acquisition
Number of subjects: 46
Study 17158823 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality evaluation of radiographs
Number of subjects: 46
Study 17158823 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of radiographic scores
Number of subjects: 46
Study 17158823 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailing of radiographic assessment
Number of subjects: 46
Study 17158823 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility of reading
Number of subjects: 46
Study 16314626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus cetuximab (arm A)
Number of subjects: 117
Study 16314626 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus placebo (arm B)
Number of subjects: 117
Study 12032037 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous psoas compartment block (CPCB) with 0.2% ropivacaine, initial loading dose of 0.4 mL/kg, followed by continuous infusion for 48 hours.
Number of subjects: 80
Study 10221186 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% preservative-free lidocaine intracameral injection
Number of subjects: 2
Study 10221186 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine peribulbar anesthesia
Number of subjects: 2
Study 8750418 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior encoding of target sounds with associated names
Number of subjects: 0
Study 8750418 — intervention group
Group type: COMPARATOR
Intervention: Prior exposure to names alone (without environmental sounds)
Number of subjects: 0
Study 8750418 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic encoding of sounds
Number of subjects: 0
Study 8750418 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth of encoding manipulations
Number of subjects: 0
Study 2170516 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide 25-50 mg/day plus triamterene 50-100 mg/day, with alpha-methyldopa 0.5-2.0 g/day in one-third of patients)
Number of subjects: 822
Study 2170516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 429218 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation with 95% O2 and 5% CO2
Number of subjects: 55
Study 429218 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion with papaverin and dextran
Number of subjects: 55
Study 31601162 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level intervention (CLI)
Number of subjects: 119
Study 31601162 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level intervention (ILI) + Community-level intervention (CLI)
Number of subjects: 119
Study 31601162 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 119
Study 31801937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 51
Study 31801937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27686182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine (0.5 mL IM)
Number of subjects: 204
Study 27686182 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 204
Study 25965782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist's exercise recommendation with exercise motivation package
Number of subjects: 162
Study 25965782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologist's exercise recommendation
Number of subjects: 162
Study 25965782 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 162
Study 23044702 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strengthening
Number of subjects: 32
Study 23044702 — intervention group
Group type: COMPARATOR
Intervention: Concentric strengthening
Number of subjects: 32
Study 21216000 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision (intervention group)
Number of subjects: 1245
Study 21216000 — intervention group
Group type: COMPARATOR
Intervention: Control group (circumcision after 24 months)
Number of subjects: 1245